According to our recent payer coverage analysis for type 2 Diabetes (SGLT2 and Combo) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for type 2 Diabetes (SGLT2 and Combo) treatments shows that under the pharmacy benefit, about 47% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: In January 2020, the FDA approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) to lower blood sugar in adults with type 2 diabetes, along with diet and exercise. The drug is marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Co., and it is the first triple combination product in the indication.